



Bio-resorbable polymer stents: a review of material progress and prospects



Sean McMahon^{a,d,1}, Nicky Bertollo^{b,1}, Eoin D. O' Cearbhaill^c, Jochen Salber^f,
Luca Pierucci^d, Patrick Duffy^{a,d}, Thomas Dürig^e, Vivian Bi^e, Wenxin Wang^{a,*}

^a The Charles Institute of Dermatology, School of Medicine, University College Dublin, Belfield, Dublin, Ireland

^b School of Medicine, UCD Centre for Biomedical Engineering, University College Dublin, Belfield, Dublin, Ireland

^c School of Mechanical and Materials Engineering, UCD Centre for Biomedical Engineering, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin, Ireland

^d Ashland Specialties Ireland Ltd., Laboratory A, Synergy Centre, Tallaght, Dublin, Ireland

^e Ashland Specialty Ingredients, Global Pharma R&D, Wilmington, USA

^f Zentrum für klinische Forschung, Ruhr-Universität Bochum and Universitätsklinikum Knappschafts-Krankenhaus, Bochum, Germany

ARTICLE INFO

Article history:

Received 7 February 2017

Received in revised form 28 February 2018

Accepted 13 May 2018

Keywords:

Coronary artery disease

Bio-resorbable stents

Drug-eluting stents

Bio-resorbable polymers

Polymer processing

PLLA

ABSTRACT

Coronary Artery Disease (CAD) remains the leading cause of death in the developed world. The advent of drug-eluting Bio-resorbable Stents (BRSs) heralded a significant development in the field of CAD, representing a step-change in the treatment paradigm and offering significant improvements in patient outcome. But, as noted by a Task Force sanctioned by the European Commission in 2017, their widespread clinical deployment has primarily been hampered by a lack of randomised clinical trial data demonstrating improved efficacy over traditional permanent drug-eluting stents (DESS). To date, only the Abbott BVS, voluntarily withdrawn from sale in 2017, has undergone such rigorous evaluation, and which showed inferior outcomes at 2–3 years. This timely review paper addresses leading BRS polymer stent technologies to highlight the trends in design strategies and current technological advancements aimed at overcoming such performance limitations. This review examines the leading BRS technologies to gauge the progression of polymer materials technology and strategies in this field. To highlight emerging trends with respect to constituent materials, the developmental history of each stent is discussed briefly, providing context to progress. Many stent features that relate to material selection including material types, material combinations, drugs, architecture features, strut thickness, processing techniques and radiopacity are considered and compared. Following detailed review of these stents, materials and related features are summarised and discussed to highlight the changing clinical needs, current targets and challenges ahead.

© 2018 Published by Elsevier B.V.

Contents

1. Introduction.....	80
2. Bio-resorbable polymer stents.....	81
2.1. Abbott Vascular (Santa Clara, CA, USA).....	81
2.1.1. ABSORB (1.0).....	81
2.1.2. ABSORB BVS (1.1).....	81
2.2. Elixir Medical (Milpitas, CA, USA).....	82

Abbreviations: PAE, poly(anhydride ester); PDLA, poly(D-lactide); PLLA, poly(L-lactide); PDLLA, poly(D,L-lactide); PGA, poly(glycolide); PLGA, poly(D,L-lactide-co-glycolide); PCL, poly(ϵ -caprolactone); PLCL, poly(L-lactide-co- ϵ -caprolactone); PTD-PC, desaminotyrosine polycarbonate polymer; SA/AA, salicylic acid/adipic acid.

* Corresponding author at: The Charles Institute of Dermatology, School of Medicine, University College Dublin, Ireland.

E-mail address: wenxin.wang@ucd.ie (W. Wang).

¹ These authors contributed equally to this work.

2.2.1.	DESolve 150/DESolve Nx	82
2.2.2.	DESolve 100	82
2.2.3.	DESolve Cx	82
2.2.4.	DESolve NTx	82
2.3.	Reva Medical Inc. (San Diego, CA, USA)	82
2.3.1.	REVA	82
2.3.2.	ReZolve	82
2.3.3.	ReZolve 2	82
2.3.4.	Fantom	82
2.4.	Meril Life Sciences (Vapi, Gujarat, India)	83
2.4.1.	MeRes stent	83
2.4.2.	MeRes100	83
2.5.	Amaranth Medical, Inc. (Mountain View, CA, U.S.A.)	83
2.5.1.	FORTITUDE	83
2.5.2.	APTITUDE	83
2.5.3.	MAGNITUDE	83
2.6.	Huaan Biotechnology Group Co., Ltd. (Laiwu, China)	83
2.6.1.	XINSORB	83
2.7.	Bioabsorbable Therapeutics Inc. (Menlo Park, CA, USA)	84
2.7.1.	IDEAL (1st Gen) stent	84
2.8.	Manli Cardiology (Singapore)	84
2.8.1.	Mirage BRMS	84
2.9.	Kyoto Medical Planning Co., Ltd. (previously known as Igaki Medical Planning Co., Ltd, Japan)	84
2.9.1.	Igaki-Tamai	84
2.10.	Arterius Ltd. (Bradford, UK)	84
2.10.1.	ArterioSorb	84
2.11.	Arterial Remodelling Technologies inc. (Paris, France)	84
2.11.1.	ART Pure	84
2.12.	OrbusNeich (Fort Lauderdale, FL, USA)	85
2.12.1.	ON-AVS	85
2.13.	S3V Vascular technologies (Bangalore, India)	85
2.13.1.	Avatar	85
2.14.	480 Biomedical (Watertown, MA, USA)	85
2.14.1.	BRS	85
2.15.	Cardionovum GmbH (Bonn, Germany)	85
2.15.1.	ReNATURAL (P)	85
3.	Resorbable materials used in bio-resorbable stents	86
4.	Bio-resorbable stent fabrication materials	86
4.1.	Poly(L-lactide) PLLA, poly(D-lactide) PDLA and poly(D,L-lactide) PDLA	86
4.2.	Poly(desaminotyrosyl-tyrosine ethyl ester) carbonate PTD-PC	87
4.3.	Poly(anhydride ester) PAE	88
4.4.	Poly(ϵ - caprolactone) (PCL)	88
4.5.	Poly(L-lactide-co- ϵ -caprolactone) (PLCL)	88
4.6.	Poly(D,L-lactide-co-glycolide) PLGA	88
5.	Polymer based coatings	88
6.	Discussion	88
6.1.	Materials used in resorbable stents	88
6.2.	Material impact on device design and function	89
6.2.1.	Strut diameters	89
6.2.2.	Recoil	89
6.2.3.	Fracture risk and deployment limitation	89
6.2.4.	Processing to achieve improved material performance	90
6.3.	Resorption time	92
7.	Conclusions	93
	Acknowledgements	93
	References	93

1. Introduction

Coronary Artery Disease (CAD) is a condition characterised by a plaque-mediated narrowing of the vessels providing oxygenated blood to the cardiac muscles, and is the leading cause of death in the developed world [1]. Coronary stents are structural scaffolds designed primarily to prevent elastic recoil and intimal hyperplasia associated with percutaneous transluminal coronary angioplasty (PTCA) [2]. As a wound healing event, arterial patency is typically recovered within the first six months [3,4] following the procedure, which coincides with the timeframe for potential onset of in-stent

restenosis. There is a general consensus within the clinical community that the presence of a permanent stent beyond the point of mechanical support for arterial remodelling and drug release presents long-term disadvantages [5,6] while there are no significantly supported advantages to long-term continued presence of a stent [7].

While the advent of bare metallic stents (BMSs) heralded a significant advance in the treatment of CAD, the rate of clinically indicated target lesion repeat revascularisation resulting from in-stent restenosis and neointimal tissue growth remained high [8]. Drug eluting stents (DESs) have been successful in reducing the rate

Download English Version:

<https://daneshyari.com/en/article/7825708>

Download Persian Version:

<https://daneshyari.com/article/7825708>

[Daneshyari.com](https://daneshyari.com)